drugset / Trial / NCT07412197
Preventive Dendritic Cell Vaccination for Lynch Syndrome
Phase 1/2
Not yet recruiting
13 enrolled
Radboud University Medical Center
Dutch Cancer Society · collab
NaSingle-groupOpen-labelPrevention
Summary
The aim of this study is to assess safety, feasibility and immunogenicity of vaccination with neopeptide-loaded dendritic cells in Lynch Syndrome subjects who are known to be carrier of a germline MMR-gene mutation without signs of disease.
Timeline
- Start
- 2026-08
- Primary completion
- 2029-12
- Completion
- 2036-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DCVax-L | Vaccine | — | Other |